Altea and Elan form joint venture

Altea (Atlanta, Ga.) and ELN will form a joint venture to develop up to five DNA vaccine and gene therapy products using Altea's MicroPor non-invasive transdermal drug delivery technology with ELN's formulation technology. The joint venture will focus on preventive and therapeutic vaccines for infectious diseases and cancer, and either ELN or third-party partners will market resulting products. ...